Ronald de Wit

发表

Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).

D. Bajorin, H. Nishiyama, A. Balar, 2019, Journal of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer.

M. Lolkema, P. Hamberg, N. Mehra, 2023, JCO Precision Oncology.

Darolutamide does not interfere with OATP‐mediated uptake of docetaxel

A. Gibson, A. Sparreboom, Shuiying Hu, 2024, International Journal of Cancer.

Darolutamide added to docetaxel augments antitumor effect in models of prostate cancer through cell cycle arrest at the G1-S transition.

E. Martens-Uzunova, M. V. van Royen, W. V. van Weerden, 2023, Molecular cancer therapeutics.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

S. Culine, J. Hainsworth, R. Huddart, 2017, The Lancet.

Prognostic factors in advanced seminoma: An analysis from the IGCCCG Update Consortium.

L. Collette, R. Huddart, D. Feldman, 2020 .

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study

A. Balar, P. Grivas, M. S. van der Heijden, 2024, BMC cancer.

Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia.

M. Joerger, S. Koolen, S. Sassen, 2023, European urology oncology.

A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide.

R. Mathijssen, S. Koolen, S. Buck, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.